These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26144345)

  • 1. Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase.
    Bagdanoff JT; Jain R; Han W; Poon D; Lee PS; Bellamacina C; Lindvall M
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3626-9. PubMed ID: 26144345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.
    Bagdanoff JT; Jain R; Han W; Zhu S; Madiera AM; Lee PS; Ma X; Poon D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3788-92. PubMed ID: 26259804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative.
    Kinoshita T; Warizaya M; Ohori M; Sato K; Neya M; Fujii T
    Bioorg Med Chem Lett; 2006 Jan; 16(1):55-8. PubMed ID: 16242327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
    Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
    Deng X; S Gray N
    Expert Opin Ther Pat; 2012 Jun; 22(6):709-13. PubMed ID: 22607035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazolo[1,5-a]pyridines as p38 kinase inhibitors.
    Stevens KL; Jung DK; Alberti MJ; Badiang JG; Peckham GE; Veal JM; Cheung M; Harris PA; Chamberlain SD; Peel MR
    Org Lett; 2005 Oct; 7(21):4753-6. PubMed ID: 16209527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
    Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
    Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure.
    Chen F; Hancock CN; Macias AT; Joh J; Still K; Zhong S; MacKerell AD; Shapiro P
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6281-7. PubMed ID: 17000106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
    Lovering F; Kirincich S; Wang W; Combs K; Resnick L; Sabalski JE; Butera J; Liu J; Parris K; Telliez JB
    Bioorg Med Chem; 2009 May; 17(9):3342-51. PubMed ID: 19364658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
    Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
    Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
    J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel target site for ATP-independent ERK2 inhibitors.
    Yoshida M; Nagao H; Sugiyama H; Sawa M; Kinoshita T
    Biochem Biophys Res Commun; 2022 Feb; 593():73-78. PubMed ID: 35063772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
    Miglani R; Cliffe IA; Voleti SR
    Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling and crystal structure of ERK2-hypothemycin complexes.
    Rastelli G; Rosenfeld R; Reid R; Santi DV
    J Struct Biol; 2008 Oct; 164(1):18-23. PubMed ID: 18571434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
    Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.